Premium Baricitinib API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Premium Baricitinib API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Baricitinib (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Janus Kinase (JAK) Inhibitor

Indications: Moderate to Severe Rheumatoid Arthritis (RA)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Baricitinib distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Baricitinib is a small-molecule Active Pharmaceutical Ingredient (API) classified pharmacologically as a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

It functions as a selective, reversible inhibitor of Janus kinases, specifically targeting the JAK1 and JAK2 intracellular enzymes. These enzymes are critical for transmitting signals from cytokines and growth factors to the cell nucleus via the JAK-STAT (Signal Transducer and Activator of Transcription) pathway.

In the pathology of severe rheumatoid arthritis, the JAK-STAT pathway is overactive, resulting in chronic joint inflammation and structural tissue destruction. By blocking the ATP-binding site of JAK1 and JAK2, Baricitinib effectively disrupts this inflammatory signaling cascade.

For pharmaceutical formulation, this API serves as the primary active ingredient for oral therapeutics directed at RA patients who exhibit an inadequate response to traditional treatments, such as methotrexate or TNF inhibitors. Baricitinib is standardly formulated into 2 mg and 4 mg immediate-release oral solid dosage forms.

Sourcing Baricitinib in Pakistan: Morgan’s Supply Network

Procuring specialty APIs for local commercial manufacturing often involves navigating extended lead times, customs bottlenecks, and complex regulatory compliance. As a dedicated pharmaceutical raw material supplier, sourcing Baricitinib Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners that operate in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with us as your supply vendor secures several operational provisions for your facility:

• DRAP Registration Support: Morgan facilitates the transfer of all necessary regulatory documentation required for local compliance. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. This ensures your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every delivery provided by Morgan includes a rigorously verified Certificate of Analysis (CoA) from the manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during your blending, granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Baricitinib API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
• CAS Number: 1187594-09-7
• Appearance: White to off-white or light yellowish crystalline powder
• Molecular Formula: C16H17N7O2S
• Molecular Weight: 371.42 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Very slightly soluble in water; slightly soluble in specific organic solvents. Detailed solubility parameters across standard solvents and aqueous buffers are documented in the technical data sheet to assist your R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

Baricitinib is a highly potent immunomodulatory compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (protecting from extreme heat and moisture) to prevent chemical degradation.
• Occupational Safety: Personnel handling the raw powder must follow advanced containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated containment isolators to prevent inhalation of airborne particulates and cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.